Shares of healthcare product and device company Abbott Laboratories (NYSE:ABT) fell 8.3% in the afternoon session after the company reported fourth-quarter revenue that missed Wall Street's ...

Abbott shares fell after quarterly sales and early 2026 earnings guidance missed estimates, even as the company forecast ...

Pricing challenges in Abbott’s nutrition business and lower than expected sales of continuous glucose monitors drove down the ...

Abbott Communications finally launched on Y&R, and it's still completely pointless. What exactly is Sally Spectra even the ...

Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.

Abbott’s stock has fallen by over 7% despite reporting strong fiscal year 2025 (FY25) revenues of $44.32bn, representing a ...

Abbott Laboratories (ABT) on Thursday reported fourth-quarter net income of $1.78 billion. The Abbott Park, Illinois-based ...

Abbott projects full-year 2026 organic sales growth to be in the range of 6.5% to 7.5%. Abbott projects full-year 2026 adjusted diluted earnings per share of $5.55 to $5.80 and first-quarter 2026 ...

Abbott Laboratories (ABT) stock falls as underperformance in the company's Nutrition segment leads it to record lower than expected Q4 sales. Read more here.

Abbott Laboratories forecast a 1Q profit that was lower than Wall Street expected and missed 4Q sales estimates after its ...

The Medical Devices business remained a standout performer at Abbott, with Q4 sales up 12.3% to $5.68 billion. Abbott ...

Abbott reports fourth-quarter sales that miss analysts’ estimates.